Type 2 diabetes mellitus (T2DM) has gone beyond the professional interests of one specialty. T2DM, cardiovascular (CV) diseases and chronic kidney disease, considered from the standpoint of a single cardio-reno-metabolic continuum, place a heavy economic burden on society. At the same time, the improvement of diagnostic methods and medical technologies led to distinct decrease in the frequency and mortality from a number of complications of T2DM, including myocardial infarction and stroke, but other states took their place. Thus, heart failure (HF) has taken the position of one of the most frequent complications with average prevalence of 24–40 % and significant predominance of HF with preserved ejection fraction (HFpEF). According to this paradigm, HFpEF is not a disease of diastolic dysfunction, but a systemic disease, the central element of which is impaired renal function. All this together has a potential value for choosing the optimal therapy. In recent years the results of specially designed studies assessing the CV-safety of antidiabetic drugs from the groups of dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like preptide-1 (GLP-1) receptor agonists and sodium – glucose co-transporter-2 (SGLT2) inhibitors have become known. These drugs, except for SGLT2 inhibitors, by their mechanism of action affecting insulin resistance and hyperglycemia, demonstrated neutral or negative result on the frequency of hospitalizations due to HF. The EMPA-REG OUTCOME study with SGLT2, which has a special insulin-independent mechanism of action, demonstrated not only the efficacy and CV-safety of the drug in the form of a decrease in CV mortality by 38 %, but also a decrease in hospitalizations for HF by 35 %. Further studies with SGLT2 inhibitors confirmed positive effect on HF, indicating a class effect of the drugs. The recently completed study DECLARE-TIMI 58 proved the advantages of using dapagliflozin for the primary and secondary prevention of HF. This review highlights the prevalence of HF in diabetes mellitus, a new concept of the pathophysiology of HF, the main groups of sugar-lowering drugs and their effect on CV outcomes, in particular on HF.
Эффективность и переносимость Арифама у пациентов с артериальной гипертонией старше 55 лет: основные результаты наблюдательной программы АРБАЛЕТ Кобалава Ж. Д., Толкачева В. В., Багманова Н. Х., Хасанова Э. Р.Цель. В проспективной наблюдательной программы АРБАЛЕТ проводилась оценка в условиях реальной клинической практики эффективности и безопасности терапии с использованием фиксированной комбинации амлодипин/ индапамид (Арифам) у амбулаторных больных с артериальной гипертонией (АГ) старше 55 лет. Материал и методы. В наблюдение было включено 2217 пациентов -692 (31%) мужчин и 1521 (69%) женщин. Оценивали изменение в ходе 3-месячной терапии систолического и диастолического артериального давления (АД), частоту достижения целевых уровней АД (<140/90 мм рт.ст.), частоту положительного ответа на лечение при клиническом измерении АД и амбулаторном измерении АД и проводили оценку эффективности терапии врачом и пациентом. Результаты. Применение фиксированной комбинации Арифам позволило достичь целевого АД к 3-му месяцу лечения у 89,81% пациентов, достичь положительного ответа через 2 нед. у 73,77% больных, через 1 мес. -у 94,88% больных. По данным домашнего самоконтроля, целевого уровня АД (<135/85 мм рт.ст.) удалось достичь у 79,47% пациентов. Количество пациентов с пульсовым АД <60 мм рт.ст. увеличилось через 3 мес. лечения до 81,97%. Преждевременно выбыли 48 (2,17%) пациентов, из-за развития нежелательных явлений -6 (0,28%) из общего числа включенных в программу. Заключение. Программа АРБАЛЕТ продемонстрировала высокую эффективность, хорошую переносимость и целесообразность использования фиксированной комбинации Арифам у амбулаторных пациентов с АГ старше 55 лет.Российский кардиологический журнал. 2018;23(12):64-74 http://dx.
Purpose To assess the incidence of over and underdiagnosis of heart failure (HF) in hospital patients with type 2 diabetes mellitus (T2DM) Methods In the single-center prospective study (registry) from 01.08.2018 to 31.01.2019 we included 1008 patients admitted to the city hospital. Key inclusion criteria: a history of T2DM, age ≥40 years. Key exclusion criteria: any other disorders of carbohydrate metabolism, age <40 years, acute coronary syndrome, functionally dependent patients. We assessed the presence of HF in the diagnosis at admission by the following criteria: the presence of HF stage C or D (ACCF/AHA) and at least II NYHA functional class. All patients underwent standard echocardiography and NT-proBNP assessment at 1–3 days after admission. The diagnosis of HF was established by the 2016 ESC HF Guidelines. After the examination, the patients were divided into subgroups: “Confirmed HF” (HF was in the diagnosis, its presence was confirmed), “Unconfirmed HF” (HF was in the diagnosis, its presence was excluded), “First diagnosed HF” (HF was not in the diagnosis, its presence was confirmed) and “Absent of HF” (HF was not in the diagnosis and its presence was excluded). We also analyzed the reasons for admissions in all patients. Results The presence of HF in the diagnosis at admission was in 68.8% (n=693) of patients and, accordingly, it was absent in 31.2% (n=315). By the ESC HF Guidelines HF was diagnosed in 68.1% (n=686) and, accordingly, in 31.9% (n=322) it was excluded. The analysis results by the diagnosis at admission are presented in Fig. 1. The analysis of the reasons for admission depending on the HF status is presented in Fig. 2. In 35 patients admitted with HF decompensation the presence of HF was not confirmed and the diagnosis was revised: atrial fibrillation in 11 (31,4%) patients, exacerbation of COPD – 7 (20,0%), pulmonary embolism – 6 (17,1%), pneumonia – 4 (11,4%), kidney diseases – 4 (11,4%), and asthma – 3 (8,7%). Conclusion Among hospitalized patients with T2DM, there is a similar incidence of over and underdiagnosis of HF. Patients with first diagnosed HF were more likely to be admitted for reasons unrelated to cardiovascular diseases (CVD), most often with hyperglycemia (Fig. 2). Patients with unconfirmed HF – for reasons related to CVD, while the reason for admission in a quarter of patients was HF decompensation (Fig. 2). Despite the availability of examination for HF, the problem of its diagnosis is still relevant. Funding Acknowledgement Type of funding sources: None. Figure 1Figure 2
To estimate the prevalence and echocardiographic phenotypes of heart failure (HF) in patients with type 2 diabetes mellitus (T2DM) admitted to the hospital.
To estimate the prevalence of carbohydrate metabolism disorders and the conformity of baseline blood pressure (BP), low-density lipoproteins (LDL), and HbA 1c to the target levels in patients with established cardiovascular diseases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.